BNCT is a therapy which selectively destroys the cancer cells by high LET and short track range particles through
10B(n, α)
7Li reaction. Their ranges of particle and
7Li nucleus are respectively 9μm and 4μm, and do not exceed the diameter of general cancer cell. For this reason, selective accumulation of
10B compound in tumor cell or tissue is necessary. The clinical study which started in the U.S.A. was continued by the researchers in Japan, and BNCT has entered into new era at the beginning of 21
st century supported by the results of basic and clinical researches, especially those in the end of 1980s and 1990s. An area of clinical study has expanded from malignant brain tumor and malignant melanoma to recurrent H & N tumor after standard treatment, liver cancer with multiple lesions, malignant pleural mesothelioma, etc. For a long time, research reactor has been used as neutron source. But it is quite inconvenient as clinical facility because of heavy task for safety control and limited site for construction. To dissolve this problem, the accelerator for BNCT has been developed by Kyoto University Research Reactor Institute and Sumitomo Heavy Industries, Ltd. as a substitute of research reactor first in the world.
View full abstract